ClinicalTrials.gg
RecruitingNCT04831580ROCCUpdated Jul 30, 2026

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

An interventional study of da Vinci and open surgery in Cervical Cancer, sponsored by GOG Foundation. Recruiting at 156 sites in 4 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by GOG Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
840
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
61st of 678
840 · median 71
Started
2022
with 35 others
No phase
246 of 834
51 open now
Primary completion
2029-03
later than 183 of 217 live
Registered
611th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 61st largest by planned enrollment of the 678 interventional ones that give a count, is one of 36 that started in 2022, is one of 246 with no phase, reaches primary completion later than 183 of the 217 other live ones, and was the 611th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.

Read the detailed description

This is a multi-center, open-label, randomized, non-inferiority clinical trial with the hypothesis that robotically assisted hysterectomy with tumor containment prior to colpotomy is non-inferior to abdominal hysterectomy with respect to disease free survival.

At the commencement of surgery, a thorough inspection of all peritoneal surfaces should be performed. The location of any suspected metastatic disease should be documented in the operative report and a biopsy should be performed to confirm the diagnosis. If intraperitoneal disease is detected, the radical hysterectomy should be abandoned. In patients with macroscopic evidence of metastatic disease to the lymph nodes, intraoperative frozen section should be performed to confirm the presence of metastatic disease. Intraoperative management will be left to the discretion of the surgeon. Patients who have confirmed macroscopic lymph node metastases intraoperatively will be excluded from final analysis and replaced due to the controversy surrounding the decision to perform a radical hysterectomy in this setting. Patients in whom the hysterectomy is abandoned will be deemed non-evaluable and excluded from final analysis and will be replaced. For all patients, the surgeon should document operative time from incision to close, detailed description of operative findings, intraoperative complications, and blood loss. For patients randomized to the robotic arm, the surgeon should document the use of and specify the type of vaginal manipulator and the reason for conversion to laparotomy (if applicable). Transcervical manipulators are not permitted.

Standard arm: Radical or simple hysterectomy is performed as per standard technique (peon radical hysterectomy (Piver type 2 or 3 or Querleu \& Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved +/- transposition. Prior to colpotomy, the vagina must be closed over the tumor (ie, Wertheim clamps, contour stapling device).

Study arm: Radical or simple hysterectomy is performed as per standard robotic technique (Querleu \& Morrow Type B or C) with salpingectomy +/- oophorectomy. Ovaries may be removed or preserved +/- transposition. Colpotomy may be made intracorporally or vaginally. Vagina must be closed prior to intracorporeal colpotomy (see below, #10)

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must have confirmed adenocarcinoma (usual/classic/NOS), squamous cell carcinoma, adenosquamous carcinoma (Including glassy cell)
  2. Patient must be FIGO Stage IA2, IBI, IB2 (2018 staging) without evidence of definitive parametrial, vaginal, nodal or distant on exam or imaging. Patients with tumor size less than or equal to 4 cm confirmed on MRI prior to randomization are eligible.
  3. Patient must have uterine size \<12 cm AND felt to be appropriate for vaginal delivery of the specimen per investigator.
  4. Patient must be suitable surgical candidate with preoperative assessments such as labs and performed per institutional standard and agree to be randomized to undergo open or robotic radical (or simple) hysterectomy.

    NOTE: Simple hysterectomy will be allowed in patients who meet the following criteria:

    1. pelvic MRI must demonstrate a maximal tumor size of 2 cm or less AND
    2. less than 50% stromal invasion on MRI if tumor present or less than 10 mm of stromal invasion if an excisional (cold knife or LEEP) has been performed.

    Submission of source documents in the GOG Partners Source Document Portal will be required prior to randomization for review and confirmation of simple hysterectomy being met (see Section 6.0 for instructions).

  5. Patient must be age 18 years or older.
  6. Patient must have performance status 0-1.
  7. Patient must have a negative urine pregnancy test within 30 days of surgery in pre-menopausal women.
  8. Patient must have signed an approved and authorization permitting the release of personal health information.

Exclusion criteria

Exclusion Criteria:

  1. Patients with any tumor histology other than those listed above, specifically excluding the following histologies: neuroendocrine, other adenocarcinoma (gastric type, endometrioid, clear cell, serous, signet ring, minimal deviation)
  2. Patients with FIGO stage 1A1, IB3, II-IV (2018 staging).
  3. Patient with inability to receive an MRI.
  4. Patients with a tumor size greater than 4cm or on MRI confirmed prior to randomization are excluded. Patients with definite evidence of vaginal/parametrial involvement on MRI are excluded; if MRI findings are not definitive, then clinical examination must also not reveal parametrial or vaginal extension).
  5. Patients with evidence of disease (imaging or histologically positive lymph nodes).
  6. Patients with a history of prior pelvic or abdominal radiotherapy.
  7. Patients with a prior \< 5 years from enrollment with the exception of non-melanoma skin cancer.
  8. Patients who are unable to withstand prolonged lithotomy or steep trendelenberg.
  9. Patient compliance and geographic proximity that do not allow adequate follow-up.
  10. Patients with poorly controlled with \<500.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
840 participants (estimated)

Study arms

  • Active comparator
    Open radical or simple hysterectomy

    Other: open surgery

  • Experimental
    Robotic radical or simple hysterectomy

    Device: da Vinci

Interventions

  • Deviceda Vinci

    Minimally invasive robotic-assisted radical or simple hysterectomy

  • Otheropen surgery

    open radical or simple hysterectomy

06

What researchers measure

Primary outcomes

  1. Survival

    3 year disease-free survival

    Time frame: 36 months

07

Study locations

136 of 156 sites recruiting
  • Western Regional Medical Center LLC
    Goodyear, Arizona 85338, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • City of Hope
    Duarte, California 91010, United States
    Recruiting
    • Raechelle Tinsley · ContactRTinsley@coh.org
    • Mihae Song, MD · Principal investigator
  • University of California San Diego Medical Center
    Encinitas, California 92024, United States
    Recruiting
  • City of Hope Orange County Lennar Foundation Cancer
    Irvine, California 92618, United States
    Recruiting
    • Raechelle Tinsley · Contactrtinsley@coh.org
    • Mihae Song, MD · Principal investigator
  • University of California San Diego Medical Center
    La Jolla, California 92037, United States
    Recruiting
  • University of California San Diego Moores Cancer Center
    La Jolla, California 92093, United States
    Recruiting
  • UCLA Gynecologic Oncology Clinic
    Los Angeles, California 90095, United States
    Recruiting
  • Hoag Gynecologic Oncology
    Newport Beach, California 92633, United States
    Recruiting
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
    Recruiting
  • Palo Alto Medical Foundation
    Palo Alto, California 94040, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Stanford Hospital
    Palo Alto, California 94305, United States
    Recruiting
  • University of California San Diego Medical Center
    San Diego, California 92103, United States
    Recruiting
  • California Pacific Medical Center-Research Institute
    San Francisco, California 91409, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • City of Hope - Upland
    Upland, California 91786, United States
    Recruiting
    • Raechelle Tinsley · Contactrtinsley@coh.org
    • Mihae Song, MD · Principal investigator
  • University of California San Diego Medical Center
    Vista, California 92081, United States
    Recruiting
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
    Recruiting
  • Hartford Healthcare Cancer Institute at Hartford Hospital
    Hartford, Connecticut 06106, United States
    Recruiting
  • Hartford Healthcare Medical Group-Manchester
    Manchester, Connecticut 06042, United States
    Recruiting
  • Harford HealthCare Cancer Institute at the Hospital of Central Connecticut
    New Britain, Connecticut 06053, United States
    Recruiting
  • Ascension Medical Group St. Vincent's Obstetrics and Gynecology
    Jacksonville, Florida 32204, United States
    Recruiting
  • Mercy Hospital
    Miami, Florida 33133, United States
    Recruiting
  • Mount Sinai Comprehensive Cancer Center
    Miami, Florida 33140, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • South Miami Hospital
    Miami, Florida 33143, United States
    Recruiting
  • South Miami Hospital
    Miami, Florida 33143, United States
    Recruiting
  • Mercy Hospital
    Miami, Florida 33173, United States
    Recruiting
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
    Recruiting
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
    Recruiting
  • Orlando Health Cancer Center
    Orlando, Florida 32806, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Orlando Health Winnie Palmer Hospital for Woman and Babies
    Orlando, Florida 32806, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Tampa General Hospital
    Tampa, Florida 33606, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Georgian Cancer Center at Augusta University
    Augusta, Georgia 30912, United States
    Recruiting
  • Southeastern Regional Medical Center LLC
    Newnan, Georgia 30265, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • St. Vincent Hospital and Health Care Center Inc
    Indianapolis, Indiana 46260, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • St. Vincent Hospital and Health Care Center, Inc
    Indianapolis, Indiana 46260, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • St. Elizabeth Healthcare
    Edgewood, Kentucky 41017, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
    Recruiting
  • Baptist Health
    Lexington, Kentucky 40503, United States
    Recruiting
  • LSU Health New Orleans
    New Orleans, Louisiana 70112, United States
    Recruiting
    • Dina Brackman · Contactdbrack@lsuhsc.edu
    • Amelia Jernigan, MD · Principal investigator
  • Willis-Knighton Physician Network Gynecologic Oncology Associates
    Shreveport, Louisiana 71118, United States
    Recruiting
    • Carrie Key, RN · Contactckay@wkhs.com
    • Destin Black, MD · Principal investigator
  • Maine Medical Partners-Woman's Health-Division of Gynecologic Oncology
    Scarborough, Maine 04074, United States
    Recruiting
    • Robin Donovan · Contactdonovr@mmc.org
    • Leslie Bradford, MD · Principal investigator
  • Baystate Medical Center
    Springfield, Massachusetts 01199, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • M Health Fairview University of Minnesota Medical Center-East Bank Hospital
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Erin Zielinksi · Contacteezielin@umn.edu
    • Colleen Rivard, MD · Principal investigator
  • M Health Fairview University of Minnesota Medical Center-East Bank Hospital
    Minneapolis, Minnesota 55455, United States
    Recruiting
    • Erin Zielinksi · Contacteezielin@umn.edu
    • Collen Rivard, MD · Principal investigator
  • David C. Pratt Center
    St Louis, Missouri 63141, United States
    Recruiting
  • Center of Hope
    Reno, Nevada 89511, United States
    Recruiting
  • Memorial Sloan Kettering (Basking Ridge)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • Memorial Sloan Kettering (Bergen)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87131, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwell Health/South Shore University Hospital
    Bay Shore, New York 11706, United States
    Recruiting
  • Northwell Health Physician Partners/Gynecological Oncology at Brightwaters
    Brightwaters, New York 11718, United States
    Recruiting
  • Laura and Issac Perlmutter Cancer Center at NYU Langone
    Brooklyn, New York 11220, United States
    Recruiting
  • NYU Langone Ambulatory Care Bay Ridge
    Brooklyn, New York 11220, United States
    Recruiting
  • NYU Langone Hospital-Brooklym
    Brooklyn, New York 11220, United States
    Recruiting
  • Memorial Sloan Kettering (Commack)
    Commack, New York 11725, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • Memorial Sloan Kettering (Westchester)
    Harrison, New York 10604, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • Northwell Health/Huntington Hospital
    Huntington, New York 11743, United States
    Recruiting
  • Memorial Sloan Kettering (Monmouth)
    Middletown, New York 07748, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • Northwell Health/Long Island Jewish Medical Center
    New Hyde Park, New York 11040, United States
    Recruiting
  • NHPP/Gynecologic Oncology at New Hyde Park
    New Hyde Park, New York 11042, United States
    Recruiting
  • Laura and Issac Perlmutter Cancer Center at NYU Langone-East 34th Street
    New York, New York 10016, United States
    Recruiting
  • Laura and Issac Perlmutter Cancer Center at NYU Langone
    New York, New York 10016, United States
    Recruiting
  • NYU Langone Medical Center (Tisch Hospital)
    New York, New York 10016, United States
    Recruiting
  • The Blavatnik Family - Chelsea Medical Center at Mount Sinai
    New York, New York 10029, United States
    Recruiting
  • Josie Robertson Surgery Center
    New York, New York 10065, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • Memorial Sloan Kettering Cancer Center (Main Campus)
    New York, New York 10065, United States
    Recruiting
  • Memorial Sloan Kettering (Nassau)
    Uniondale, New York 11553, United States
    Recruiting
    • Josie Anderson · Contactandersj@mskcc.org
    • Mario Leitao, MD · Principal investigator
  • Novant Health Cancer Institute
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Duke University Hospital
    Durham, North Carolina 27705, United States
    Recruiting
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
    Recruiting
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
    Recruiting
  • Novant Health Cancer Institute
    Greensboro, North Carolina 27403, United States
    Recruiting
  • Novant Health Cancer Institute
    Kernersville, North Carolina 27284, United States
    Recruiting
  • Novant Health Cancer Institute
    Mount Airy, North Carolina 27030, United States
    Recruiting
  • Novant Health Cancer Institute
    North Wilkesboro, North Carolina 28659, United States
    Recruiting
  • FirstHealth Outpatient Cancer Center
    Pinehurst, North Carolina 28374, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Novant Health Cancer Institute
    Statesville, North Carolina 28625, United States
    Recruiting
  • Novant Health Cancer Institute
    Thomasville, North Carolina 27360, United States
    Recruiting
  • Novant Health Cancer Institute
    Winston-Salem, North Carolina 27103, United States
    Recruiting
  • Summa Health Jean and Milton Copper Pavilion
    Akron, Ohio 44304, United States
    Recruiting
  • Summa Health Jean and Milton Copper Pavillion
    Akron, Ohio 44304, United States
    Recruiting
  • TriHealth Cancer Institute-Good Samaritan Hospital
    Cincinnati, Ohio 45220, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • TriHealth Cancer Institute-Thomas Comprehensive Care Center
    Cincinnati, Ohio 45220, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
  • OSU Wexner Medical Center Hospital East
    Columbus, Ohio 43203, United States
    Recruiting
  • OSU Wexner Medical Center Outpatient Care East
    Columbus, Ohio 43203, United States
    Recruiting
  • James Cancer Hospital & Solove Research Institute at The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
  • OSU Wexner Medical Center University Hospital
    Columbus, Ohio 43210, United States
    Recruiting
  • OSU Wexner Medical Center Stefanie Spielman Comprehensive Breast Center
    Columbus, Ohio 43212, United States
    Recruiting
  • OSU Wexner Medical Center Martha Morehouse Outpatient Care
    Columbus, Ohio 43221, United States
    Recruiting
  • OSU Wexner Medical Center Outpatient Care Upper Arlington
    Columbus, Ohio 43221, United States
    Recruiting
  • OSU Wexner Medical Center Outpatient Care Gahanna
    Columbus, Ohio 43230, United States
    Recruiting
  • OSU Wexner Medical Center Outpatient Care Dublin
    Dublin, Ohio 43016, United States
    Recruiting
  • JamesCare Gynecologic Oncology at Mill Run
    Hilliard, Ohio 43026, United States
    Recruiting
  • Kettering Health Cancer Center
    Kettering, Ohio 45429, United States
    Recruiting
  • OSU Wexner Medical Center Outpatient Care Lewis Center
    Lewis Center, Ohio 43035, United States
    Recruiting
  • OSU Wexner Medical Center Outpatient Care New Albany
    Westerville, Ohio 43081, United States
    Recruiting
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Legacy Good Samaritan Medical Center-Gynecological Oncology Group
    Portland, Oregon 97210, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Providence Center Institute Franz Clinic
    Portland, Oregon 97213, United States
    Recruiting

Showing the first 100 of 156 sites across 4 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Leitao MM Jr, Bixel KL, Chase DM, Quick A, McCormick C, Black D, Lim PC, Eskander RN, Gotlieb WH, LoCoco S, Martino MA, Walker JL, Copeland LJ, Monk BJ, Randall LM. ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancer. Int J Gynecol Cancer. 2025 Jul;35(7):101760. doi: 10.1016/j.ijgc.2025.101760. Epub 2025 Feb 28. PubMed 40188007 ↗
  • Boisen M, Guido R. Emerging Treatment Options for Cervical Dysplasia and Early Cervical Cancer. Clin Obstet Gynecol. 2023 Sep 1;66(3):500-515. doi: 10.1097/GRF.0000000000000790. Epub 2023 Jul 25. PubMed 37650664 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2029, 84 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 84 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2021
First posted
Apr 5, 2021
StartActual
Mar 22, 2022
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2030
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04831580
Lead sponsor
GOG Foundation
Collaborators
Intuitive Foundation
Responsible party
Sponsor
First posted
Apr 5, 2021
Start date
Mar 22, 2022
Primary completion
Mar 2029 (estimated)
Completion
Mar 2030 (estimated)
Last update
Jul 30, 2026

Study contacts

Sarin Chhab
Contact
schhab@gog.org
215-854-0770
Shanon Matkin
Contact
smatkin@gog.org
801-661-1584
Kristin Bixel, MD
study chair · Standford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion